Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cord Blood Derived Mesenchymal Stem Cells for COVID-19 Pneumonia
NCT04565665Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2020
- Primary completion
- Oct 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of mesenchymal stem cells in coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), pneumonia, sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2020; status: active, not recruiting.
02
Drugs
mesenchymal stem cells
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)pneumonia
Beyond the preview
Go deeper on NCT04565665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04565665.